January 05, 2016
1 min read
Save

CLS-TA meets primary, secondary endpoints in phase 2 clinical trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CLS-TA has met its primary endpoint of achieving a statistically significant mean change in central subfield thickness from baseline in the phase 2 Dogwood trial, according to topline data released by Clearside Biomedical.

The Dogwood trial evaluated the safety and efficacy of CLS-TA (triamcinolone acetonide) in 22 patients with macular edema associated with noninfectious uveitis. A single treatment of CLS-TA resulted in a statistically significant mean change in central subfield thickness from baseline to 8 weeks. The secondary endpoint of statistical significance in mean increase from baseline in best corrected visual acuity was also achieved, a press release said.

“The data from this clinical trial continue to provide support for the approach to treatment of certain blinding eye diseases through [suprachoroidal space] administration and the potential for an effective and safe option for the treatment of uveitis using CLS-TA,” Daniel H. White, CEO and president of Clearside, said in the release.

The company plans to submit a full data set for presentation at an upcoming meeting.